The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.

Cipla Q3 results review: The shares of the third largest pharmaceutical firm Cipla rose 2.44 per cent at Rs 1,454.20 a piece on the BSE intraday after the company delivered a solid quarterly earnings ...

Cipla has been helping extend the reach of affordable life-saving HIV/AIDS medications since 2001. The company supplies antiretroviral (ARV) medicines to 64 countries by mostly participating in the ...

Shares of drugmaker Cipla Ltd. surged to the day's high, gaining as much as 4% after the company's December quarter results. The results were a beat across parameters.

HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...

Cipla Ltd.'s consolidated net profit rose 49% year-on-year in the third quarter of the current financial year, beating analysts' estimates by a substantial margin. The drugmaker posted a consolidated ...

After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...

Pharmaceutical giant Cipla on January 28 reported a consolidated net profit of Rs 1,571 crore for the quarter ended on December 31. This marks a 49 percent rise from the Rs 1,056 crore net profit ...

Shares traded at ₹358.05 on the NSE, down 2.09%. Cipla Ltd recorded its consolidated net profit for the quarter ended December 2024 at ₹1,574.59 crore as against ₹1,068.41 crore in the ...

HYDERABAD/BENGALURU, Jan 28 (Reuters) - Cipla (CIPL.NS), opens new tab, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong ...

Cipla Q3 Preview: India’s third largest pharmaceutical company, Cipla, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Tuesday, January 28, ...

Cipla's shares are currently priced at Rs 1439.65, reflecting a modest rise of 0.82%. The 7-day simple moving average is Rs 1475.93. Cipla is currently valued at Rs 1437.65, with a daily increase of 0 ...